Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer Journal Article


Authors: Ridouani, F.; Vargas, H. A.; Holzwanger, D. J.; Schöder, H.; Waters, E.; Petre, E. N.; Martin, A.; Satagopan, J.; Gonen, M.; Autio, K. A.; Chen, Y.; Slovin, S. F.; Danila, D. C.; Morris, M. J.; Scher, H. I.; Arcila, M. E.; Solomon, S. B.; Durack, J. C.
Article Title: Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer
Abstract: Background and objective: The source of tissue for genomic profiling of metastatic castration-resistant prostate cancer (mCRPC) is often limited to osseous metastases. To guide patient management, metastatic site selection and the technique for targeted bone biopsies are critical for identifying deleterious gene mutations. Our objective was to identify key parameters associated with successful large-panel DNA sequencing. Methods: We analyzed parameters for 243 men with progressing mCRPC who underwent 269 bone biopsies for genomic profiling between 2014 and 2018. Univariate and multivariate analyses were performed for clinical, imaging (bone scan; fluorodeoxyglucose [FDG] positron emission tomography [PET]; computed tomography [CT]; magnetic resonance imaging), and technical (biopsy site, number of samples, needle gauge) features associated with successful genomic profiling. Key findings and limitations: Overall, 159 of 269 biopsies (59%) generated sufficient tumor material for a genomic profile. Seventy (26%) of the failures were histopathologically negative for mCRPC and 40 (15%) had insufficient tumor for genomic profiling. Of 199 mCRPC samples submitted for molecular testing, 159 (80%) yielded a genomic profile. On univariate analysis, PSA, serum acid phosphatase, number of biopsy samples, FDG PET positivity, CT attenuation, and CT morphology were significantly associated with genomic profiling success. On multivariate analysis, higher FDG maximum standardized uptake value (odds ratio [OR] 7.51, 95% confidence interval [CI] 3.01-18.78; p < 0.001), higher number of biopsy samples (OR 4.73, 95% CI 1.49-15.02; p = 0.008), and lower mean CT attenuation (OR 0.4, 95% CI 0.18-0.89; p = 0.025) were significantly associated with sequencing success. Conclusions and clinical implications: In patients with mCRPC, bone biopsies from sites with metabolic activity and lower CT attenuation are associated with higher success rates for genomic profiling via a large-panel DNA sequencing platform. Patient summary: We identified factors associated with successful genetic testing of bone tissue for patients with metastatic prostate cancer. Our findings may help in guiding the right scan technique and biopsy site for personalized treatment planning. Published by Elsevier B.V. on behalf of European Association of Urology.
Keywords: positron emission tomography; prostate cancer; imaging; metastases; expression; patterns; bone biopsy; yield; acquisition; genomic profiling; flurodeoxyglucose; marrow biopsy
Journal Title: European Urology Oncology
Volume: 8
Issue: 2
ISSN: 2588-9311
Publisher: Elsevier BV  
Date Published: 2025-04-01
Start Page: 355
End Page: 363
Language: English
ACCESSION: WOS:001452746100001
DOI: 10.1016/j.euo.2024.07.007
PROVIDER: wos
PUBMED: 39095299
Notes: Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Jeremy Durack -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Susan Slovin
    254 Slovin
  2. Michael Morris
    582 Morris
  3. Mithat Gonen
    1031 Gonen
  4. Yu Chen
    134 Chen
  5. Karen Anne Autio
    120 Autio
  6. Heiko Schoder
    550 Schoder
  7. Stephen Solomon
    427 Solomon
  8. Elena Nadia Petre
    110 Petre
  9. Maria Eugenia Arcila
    669 Arcila
  10. Howard Scher
    1130 Scher
  11. Daniel C Danila
    155 Danila
  12. Jeremy Charles Durack
    116 Durack
  13. Axel Stephen Martin
    20 Martin